Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9882426rdf:typepubmed:Citationlld:pubmed
pubmed-article:9882426lifeskim:mentionsumls-concept:C0034721lld:lifeskim
pubmed-article:9882426lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:9882426lifeskim:mentionsumls-concept:C0016030lld:lifeskim
pubmed-article:9882426lifeskim:mentionsumls-concept:C0441655lld:lifeskim
pubmed-article:9882426lifeskim:mentionsumls-concept:C0018270lld:lifeskim
pubmed-article:9882426lifeskim:mentionsumls-concept:C0678594lld:lifeskim
pubmed-article:9882426lifeskim:mentionsumls-concept:C0205460lld:lifeskim
pubmed-article:9882426pubmed:issue1lld:pubmed
pubmed-article:9882426pubmed:dateCreated1999-2-5lld:pubmed
pubmed-article:9882426pubmed:abstractTextFibroblast growth factor-16 (FGF-16) is the most recent member of the FGF family to be cloned. Since the biologic activity of rat FGF-16 (rFGF-16) was unknown, and this protein has no apparent signal sequence, we transformed its entire cDNA into Escherichia coli for high-level expression and further characterization of this novel protein. An attempt was made to purify the expressed protein from the supernatant of mechanically lysed cells using sequential cation-exchange chromatography. This resulted in a gradual loss of the protein as precipitate throughout the purification process. In addition to precipitation during purification, sodium dodecyl sulfate polyacrylamide gel electrophoresis revealed that the partially purified materials showed a cluster of protein bands around 20k to 29k. Sequence analysis of the major bands indicated that two N-terminal truncations had occurred, during E. coli fermentation, purification, or both. The largest truncation resulted in the removal of the 34 N-terminal amino acids, including the initiation codon methionine. We cloned d34 rFGF-16, expressed the gene in E. coli, and developed a purification process for this form. Even with this truncated form, precipitation was a problem. We were largely able to overcome this problem, however, by including EDTA throughout the purification process. We have characterized the structure of purified d34 rFGF-16 extensively using circular dichroism, Fourier transform infrared spectroscopy, and sedimentation velocity analysis. These studies revealed that the protein has a distinct tertiary structure, consists primarily of beta-strands, has a weak tendency to self-associate, and is fairly extended. We then performed biologic assays which showed that d34 rFGF-16 induces oligodendrocyte proliferation in vitro, and induces hepatocellular proliferation and increased liver weight in vivo. In summary, FGF-16, a novel FGF family member, has both unique structural and biological properties.lld:pubmed
pubmed-article:9882426pubmed:languageenglld:pubmed
pubmed-article:9882426pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9882426pubmed:citationSubsetIMlld:pubmed
pubmed-article:9882426pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9882426pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9882426pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9882426pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9882426pubmed:statusMEDLINElld:pubmed
pubmed-article:9882426pubmed:monthJanlld:pubmed
pubmed-article:9882426pubmed:issn0003-9861lld:pubmed
pubmed-article:9882426pubmed:authorpubmed-author:LOJJlld:pubmed
pubmed-article:9882426pubmed:authorpubmed-author:HaraSSlld:pubmed
pubmed-article:9882426pubmed:authorpubmed-author:HillDDlld:pubmed
pubmed-article:9882426pubmed:authorpubmed-author:MartinFFlld:pubmed
pubmed-article:9882426pubmed:authorpubmed-author:ItohNNlld:pubmed
pubmed-article:9882426pubmed:authorpubmed-author:ArakawaTTlld:pubmed
pubmed-article:9882426pubmed:authorpubmed-author:SpeakmanJJlld:pubmed
pubmed-article:9882426pubmed:authorpubmed-author:PhilpJ RJRlld:pubmed
pubmed-article:9882426pubmed:authorpubmed-author:DelaneyJJlld:pubmed
pubmed-article:9882426pubmed:authorpubmed-author:KonishiMMlld:pubmed
pubmed-article:9882426pubmed:authorpubmed-author:TalvenheimoJJlld:pubmed
pubmed-article:9882426pubmed:authorpubmed-author:ZhangMMlld:pubmed
pubmed-article:9882426pubmed:authorpubmed-author:DanilenkoD...lld:pubmed
pubmed-article:9882426pubmed:authorpubmed-author:OERIUSSlld:pubmed
pubmed-article:9882426pubmed:authorpubmed-author:MontestruqueS...lld:pubmed
pubmed-article:9882426pubmed:authorpubmed-author:BahriAAlld:pubmed
pubmed-article:9882426pubmed:authorpubmed-author:ChiricaMMlld:pubmed
pubmed-article:9882426pubmed:authorpubmed-author:HerndayNNlld:pubmed
pubmed-article:9882426pubmed:copyrightInfoCopyright 1999 Academic Press.lld:pubmed
pubmed-article:9882426pubmed:issnTypePrintlld:pubmed
pubmed-article:9882426pubmed:day1lld:pubmed
pubmed-article:9882426pubmed:volume361lld:pubmed
pubmed-article:9882426pubmed:ownerNLMlld:pubmed
pubmed-article:9882426pubmed:authorsCompleteYlld:pubmed
pubmed-article:9882426pubmed:pagination34-46lld:pubmed
pubmed-article:9882426pubmed:dateRevised2004-11-18lld:pubmed
pubmed-article:9882426pubmed:meshHeadingpubmed-meshheading:9882426-...lld:pubmed
pubmed-article:9882426pubmed:meshHeadingpubmed-meshheading:9882426-...lld:pubmed
pubmed-article:9882426pubmed:meshHeadingpubmed-meshheading:9882426-...lld:pubmed
pubmed-article:9882426pubmed:meshHeadingpubmed-meshheading:9882426-...lld:pubmed
pubmed-article:9882426pubmed:meshHeadingpubmed-meshheading:9882426-...lld:pubmed
pubmed-article:9882426pubmed:meshHeadingpubmed-meshheading:9882426-...lld:pubmed
pubmed-article:9882426pubmed:meshHeadingpubmed-meshheading:9882426-...lld:pubmed
pubmed-article:9882426pubmed:meshHeadingpubmed-meshheading:9882426-...lld:pubmed
pubmed-article:9882426pubmed:meshHeadingpubmed-meshheading:9882426-...lld:pubmed
pubmed-article:9882426pubmed:meshHeadingpubmed-meshheading:9882426-...lld:pubmed
pubmed-article:9882426pubmed:meshHeadingpubmed-meshheading:9882426-...lld:pubmed
pubmed-article:9882426pubmed:meshHeadingpubmed-meshheading:9882426-...lld:pubmed
pubmed-article:9882426pubmed:meshHeadingpubmed-meshheading:9882426-...lld:pubmed
pubmed-article:9882426pubmed:meshHeadingpubmed-meshheading:9882426-...lld:pubmed
pubmed-article:9882426pubmed:meshHeadingpubmed-meshheading:9882426-...lld:pubmed
pubmed-article:9882426pubmed:meshHeadingpubmed-meshheading:9882426-...lld:pubmed
pubmed-article:9882426pubmed:meshHeadingpubmed-meshheading:9882426-...lld:pubmed
pubmed-article:9882426pubmed:meshHeadingpubmed-meshheading:9882426-...lld:pubmed
pubmed-article:9882426pubmed:meshHeadingpubmed-meshheading:9882426-...lld:pubmed
pubmed-article:9882426pubmed:meshHeadingpubmed-meshheading:9882426-...lld:pubmed
pubmed-article:9882426pubmed:meshHeadingpubmed-meshheading:9882426-...lld:pubmed
pubmed-article:9882426pubmed:year1999lld:pubmed
pubmed-article:9882426pubmed:articleTitleRecombinant rat fibroblast growth factor-16: structure and biological activity.lld:pubmed
pubmed-article:9882426pubmed:affiliationAmgen Inc., Amgen Center, Thousand Oaks, California, 91320, USA. ddanilen@amgen.comlld:pubmed
pubmed-article:9882426pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9882426lld:pubmed